Company intelligence / Profile preview
Cerebral Therapeutics
- Ownership
- Private
- Development stage
- Other
Overview
Cerebral Therapeutics has completed a Phase 1/2 dose-ranging pilot study and is conducting an international Phase 2 double-blind, randomized, placebo-controlled clinical trial of CT‑010 delivered via an implantable pump directly into the brain ventricles. The approach aims to maximize efficacy and minimize systemic side effects in patients with medically refractory epilepsy. The company’s proprietary ICVRx™ platform enables targeted CNS drug delivery and may be applicable to a range of therapeutic modalities. Series C financing supports late-stage development and pipeline expansion.[7][9]
- Therapeutic areas
- Neurology
- Modalities
- Small molecules (e.g., valproic acid/valproate)Drug-device combination therapies (intracerebroventricular delivery)Potential for oligonucleotides, antibodies, enzyme therapies[7]
- Industry
- Biotech
Drug pipeline
3 assets2 more assets in the full pipeline.
Partnerships
Beyond the preview
Go deeper on Cerebral Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cerebral Therapeutics.